

TechPortal Talks: Helping Build the Foundation of High Value Patent Rights

November 2017

CallIt2



Who We Are

- 54 Years Specializing in Intellectual Property
- Eight offices nationwide
 - California
 - Los Angeles, Orange County, San Diego, San Francisco, Silicon Valley
 - Washington, D.C.
 - Seattle, WA
 - New York
- Over 275 lawyers and scientists
- Highest number of registered patent attorneys in the United States – more than 200
- Practice across a vast array of industries
- Over 95% of attorneys hold technical degrees
- Global practice through large network of Foreign Associates

Biotechnology/Medical Devices

- IP Portfolio Development, Litigation, All Areas of Technology
- Medical Device Specialty – KnobbeMedical.com

KnobbeMedical.com Resources for the Start-Up Medical Device Company

Search this site...

Home Business Capital Legal Manufacturing Medical Clinical/Regulatory IP Marketplace Blog Contact

ABOUT US 1

Resources FOR THE START-UP MEDICAL DEVICE COMPANY

Learn more about KnobbeMedical.com >

MEDICAL BLOG 2

CONFERENCES 3

MEDICAL DEVICE LAWSUIT ALERTS

- Beijing Choice Elec. Tech. Co., Ltd. v. Contec Medical Sys. USA Inc. et al. (New Lawsuit Filed)
- Trudell Medical Intl. v. D R Burton Healthcare, LLC (New Lawsuit Filed)
- Strategic Operations, Inc. v. Giannini et al. (New Lawsuit Filed)
- CAO Group, Inc. v. Biolase Technology, Inc. (New Lawsuit Filed)
- Petition for Inter Partes Review by Ulthera, Inc. of DermaFocus LLC's U.S. Patent No. 6,113,559 (Final Written Decision)
- Petition for Inter Partes Review by OrthoPediatrics Corp. et al. of K2M, Inc.'s U.S. Patent No. 9,532,816
- Arbmetrics, LLC v. Dexcom, Inc. (New Lawsuit Filed)
- Petition for Inter Partes Review by CareFusion Corporation of Baxter International, Inc.'s U.S. Patent No. 5,764,034 (Final Written Decision)
- Petition for Inter Partes Review by Becton, Dickinson and Co. of B. Braun Melsungen AG's U.S. Patent No. 9,370,641 (Inter Partes Review Instituted)
- Petition for Inter Partes Review by Becton, Dickinson and Co. of B. Braun Melsungen AG's U.S. Patent No. 8,597,249 (Inter Partes Review Instituted)

AKILI INTERACTIVE ANNOUNCES TRIAL RESULTS FOR VIDEO GAME TREATMENT OF ADHD

Akili Interactive recently announced results of a trial on the company's digital medicine product, AKL-T01. According to FierceBiotech, Akili plans to file AKL-T01 with the U.S. Food and Drug Administration (FDA) for clearance under the 510(k) medical device pathway as a novel treatment for children and adolescents with attention deficit/hyperactivity disorder (ADHD). According to the article, unlike traditional drug treatments for ADHD, AKL-T01, also known as Project: EVO, is a video game patients play on a tablet device. AKL-T01 uses storytelling and reward mechanisms, like tho...

Read more »

UPCOMING SEMINARS AND CONFERENCES

University/Non-Profit Clients

- Regents of the University of California
- EO Lawrence Berkeley National Laboratory
- UCSF Office of Innovation, Technology & Alliances
- University of Hawaii
- IMEC
- Stanford University
- University of Southern California
- Loma Linda University
- Australia National University
- Georgetown University
- Queensland University of Technology
- Caltech
- Sanford Burnham Presbys Medical Discovery Institute
- Statens Serum Institut, Denmark
- National University of Singapore
- The Walter and Eliza Hall Institute of Medical Research Australia


104 Med Device/Biotechnology Deals in 4 years Avg 1 every 2 weeks.

Relievant Medsystems, Inc.	\$36 million	Neurological technology	Cala Health, Inc.	\$18 million	Med Device: Tremor Wearable
Ablative Solutions	\$11.9 million	Medical Device: Drug Resistance	CVRx, Inc. Series G Funding	\$113 Million	Med Device: Heart Failure
Apama Medical Series C Financing	\$19.5 million	Med Device: AF Catheter	Alios BioPharma, Inc. acquired by Johnson & Johnson	\$1.75 billion	Biotech: Therapeutics for viral diseases
OptiScan Biomedical Series E	\$40 million	Med Device: ICU Blood Chemistry Monitoring	Sienna Biopharmaceuticals, Inc.	\$150 Million	Biotech
Direct Flow Medical	\$27.1 million	Medical Device: Heart	Hittite Microwave Corporation acquired by Analog Devices, Inc.	\$2 billion	Semiconductors
Apama Medical	\$20 Million	Med Devices, Technology	EKOS Corporation acquired by BTG PLC	\$220 million	Med Device: treatment of vascular thrombosis
Intact Vascular, Inc. Series B financing round	\$46 million	Med Device: Cardiovascular Implants	IDEV Technologies acquired by Abbott Labs	\$310 million	Med Device: endovascular and interventional
Solace Therapeutics	\$13 million	Med Device: Stress Urinary Incontinence	Trius Therapeutics acquired by Cubist Pharmaceuticals	\$707 million	Pharma: Antibiotic Drugs
AcuFocus Inc.	\$66 million	Med Device: Vision Tech	Anokion	\$45 million	Biotech: Autoimmune
Apama Medical Series C Financing	\$19.5 million	Med Device: Ablation catheter	Ellipse Technologies acquired by NuVasive, Inc.	\$380 Million + \$30 Million (2017)	Med Device
Action Potential Venture Capital investment in Saluda Medical	\$40 million	Med Device	Rempex Pharmaceuticals acquired by The Medicines Company	\$470 million	Pharma
Kit Check Series C Funding	\$15 Million	Medical Services, Software	Obalon Therapeutics	\$75 million	Medical Device: Weight Loss
Sienna Biopharmaceuticals, Inc.	\$46 Million	Biopharmaceuticals: Skin	iRhythm, Inc. IPO	\$107 million	Med Device: Digital Healthcare for Cardiac
NightBalance BV Series B Funding	EUR 12.5 Million	Med Device: Sleep Apnea	Ignyta, Inc. private placement and IPO	\$107 million	Pharma
Pulse Therapeutics	\$10 Million	Med Device: Stroke	Sienna Biopharmaceuticals, Inc.	\$65 million	Biotech

What Will Your Technology be Worth in 2-4 Years?

JUST YELL IT OUT!

Your Startup



Closing the Deal - “Due Diligence” – More \$, More Scrutiny

[illegible][illegible]

Closing the Deal - “Due Diligence” – More \$, More Scrutiny

Closing the Deal - “Due Diligence” – More \$, More Scrutiny

REQUESTED ITEM	STATUS / COMMENTS
III. FINANCIAL INFORMATION, ETC.	
E. Loans by the Company	
1. A list of all loans, guarantees or extensions of credit that the Company or any of its affiliates has made since its inception to any affiliate, director, officer, or shareholder of the Company or any of its affiliates.	
F. Letter Disclosures	
1. A reasonably detailed description of any and all risks, interests, claimants and other arrangements in any of the Company's or any of its affiliates' facilities and any claim of which such provisions or provisions filed with the National Labor Relations Board with respect to workers at the Company's or any of its affiliates' facilities.	
III. INTELLECTUAL PROPERTY RIGHTS	
A. Description of the Facilities	
1. A critical report detailing the current status of all United States and foreign patent applications and patents currently owned by or licensed to the Company or any of its affiliates.	
2. Copies of the file history of any of such of the unexpired United States and foreign patents, including the description by the inventor.	
3. Copies of the identity of any author, prior art and pertinent search reports, including patents or publications which relate to the subject technology which can and be seen in the file history in the public file database.	
4. Information relating to any activities by the Company or any of its affiliates or their inventors, consultants, etc. that could affect the Company's or any of its affiliates' rights in the patent applications, including but not limited to, prosecution, publication, advertising activities, etc.	
5. Copies of the report and the results of any patentability or validity searches conducted in connection with the patent applications.	
6. Copies of any patentability opinions obtained or received by the Company or any of its affiliates in connection with the Company's or any of its affiliates' technology.	
17	

REQUESTED ITEM	STATUS / COMMENTS
Company or any of its affiliates.	
1. Identification of what you consider to be the most relevant patents from a business to patent perspective.	
2. Information concerning any activities by any third parties that the Company or any of its affiliates might infringe any proprietary rights of any third parties in a commercial or non-commercial use, including in the use of products in connection with the subject technology.	
3. A list of any projects for which an availability or non-infringement opinion, verbal or written, of counsel has been sought in connection with the subject technology and reports of any non-infringement or availability opinions rendered in connection with the subject technology.	
4. An identification of each facility owner or licensee (past or present) for which a file history has been ordered by or on behalf of the Company or any of its affiliates.	
5. Information regarding any third-party activities or products which may infringe the Company's or any of its affiliates' intellectual property rights.	
IV. REAL PROPERTY	
A. Reasonably detailed description of all real property owned by the Company or any of its affiliates, including the following:	
1. Location	
2. Description	
3. Date of Purchase	
4. Description of any lease or mortgages	
5. Evidence of title to real estate, including title, buildings and fixtures (i.e., type of acquisition method).	
6. Lease or assignment of lease agreements of real property in which the Company or any of its affiliates (i) is a tenant or assignee of a lease or (ii) is a landlord.	
7. Title insurance policy covering each parcel of real property owned in connection with the acquisition of any real property by the Company or any of its affiliates and any documents thereto or other subsequent title reports.	
19	

REQUESTED ITEM	STATUS / COMMENTS
the subject technology	
1. An identification of what you consider to be the closest prior art.	
2. An identification of award and pending claims in the US and IP which you believe have the greatest impact on the Company or any of its affiliates' business.	
3. A copy of any restrictive license agreement presented by the Company or any of its affiliates in connection with the sale of any products.	
B. Description of Facilities	
1. Copies of any assignments from the inventor to the Company or any of its affiliates, forward that is available on the public file database.	
2. An identification of any University affiliation, price equity relationship, or other arrangements which would have any relationship to the Company or any of its affiliates' technology or any of its affiliates' technology.	
3. Any other information which would affect the Company's or any of its affiliates' title to the subject technology.	
C. Relationships with Third Parties	
1. Copies of any license agreements or other agreements with third parties relating to the subject technology.	
2. Information regarding any other or experiences with third parties in connection with the subject technology, including, but not limited to, cease and desist letters, offers to license, or documents from third parties.	
3. Information regarding any prior relationships in connection with any third-party parties or agreements.	
4. Confirmation whether all proprietary and technology related matters have been resolved satisfactorily and services assignment agreements.	
D. Market Conditions and Outlook	
1. Copies of the report and results of any market research or information research conducted by or on behalf of the Company or any of its affiliates.	
19	

REQUESTED ITEM	STATUS / COMMENTS
III. FINANCIAL INFORMATION, ETC.	
C. Insurance and Other Third Parties	
1. All items to which the Company or any of its affiliates is a party or otherwise bound concerning equipment (including equipment), third-party transactions, facilities and other personal property.	
D. Other Parties	
1. Schedule and description, including manner of ownership or holding, of other equipment personal property of the Company or any of its affiliates.	
E. Insurance	
1. Schedule of insurance coverage of the Company or any of its affiliates (past and present) with all policies, including information as to the nature, effective dates, coverage amounts and previous losses with respect to each policy.	
2. All insurance policies covering the Company or any of its affiliates (including policies with all current policies).	
(a) Title insurance.	
(b) Property insurance.	
(c) Corporate liability insurance.	
(d) Directors and officers liability insurance.	
(e) Stop loss, catastrophe and similar insurance, and	
(f) Other forms of insurance.	
3. Claims reported for the last five years under each of the above policies.	
F. Pending Litigation, Etc.	
1. Copies of all governmental permits, licenses, and approvals (including specifically permits, licenses, and approvals issued by any state commission or agency held by the Company or any of its affiliates, and all of its affiliates (including but not limited to, any of its affiliates' technology or any of its affiliates' technology) with any federal or state government, commission, or agency.	
21	

REQUESTED ITEM	STATUS / COMMENTS
III. FINANCIAL INFORMATION, ETC.	
E. Bank Relationships	
1. Schedule of banking relationships of the Company or any of its affiliates.	
IV. OTHER AGREEMENTS	
To the extent not covered elsewhere in this list:	
A. Agreements relating to any significant acquisition or disposition of assets or businesses by the Company or any of its affiliates during the past five years.	
B. Letters of intent, indentures of assets, offering memoranda and any other documents for any contemplated financing or acquisition or disposition of equity, assets or business by the Company or any of its affiliates.	
C. All documents relating to any transactions or relations between or among the Company and any of its affiliates and any of its affiliates' directors, officers, employees, consultants or entities that are controlled by such parties.	
D. Present or pending joint venture or partnership agreements and other such arrangements in which the Company or any of its affiliates is a party or is otherwise involved.	
E. License agreements of the Company or any of its affiliates.	
F. Management or service contracts or arrangements for management, maintenance or servicing of the Company or any of its affiliates, or any of its or their facilities.	
G. Contracts and agreements for maintenance or renovation of facilities for the Company or any of its affiliates.	
H. Inventory and nondisclosure agreements with third parties relating to technical and other proprietary information of the Company or any of its affiliates.	
I. Cooperative marketing, agency or similar contracts relating to the sale or procurement of goods or services by or on behalf of the Company or any of its affiliates.	
J. Expenses letters with financial advisors, investment bankers, lawyers, business brokers or similar advisors or service providers relating to any transaction of the type referred to in Sections A, F, G and H above.	
23	

REQUESTED ITEM	STATUS / COMMENTS
III. FINANCIAL INFORMATION, ETC.	
A. Credit Agreements and Loans to the Company	
1. All agreements of the Company or any of its affiliates relating to its or their borrowing of money, including term loans and revolving credit agreements and debt.	
2. All guarantees of any of the Company's or any of its affiliates' obligations to any of its affiliates' directors, officers, employees, consultants or entities that are controlled by such parties.	
3. All guarantees of any of the Company's or any of its affiliates' obligations, including without limitation, Letters of Credit and guarantees to other parties or persons (including specifically any of the Company's or any of its affiliates' directors, officers, employees, consultants or entities that are controlled by such parties).	
4. All documents evidencing security interests against real and personal property of the Company or any of its affiliates and an indication of where such documents are filed.	
B. Loans or Guarantees Made by the Company	
1. All agreements of the Company or any of its affiliates relating to loans by the Company or any of its affiliates, or guarantees of the obligations of other parties or persons (including specifically the Company's directors, officers, employees, consultants or entities that are controlled by such parties).	
2. All documents evidencing security interests against real and personal property of the Company or any of its affiliates and an indication of where such documents are filed.	
3. All documents relating to any transactions or relations between or among the Company and any of its affiliates and any of its affiliates' directors, officers, employees, consultants or entities that are controlled by such parties.	
C. Other Information	
1. Any other information or documents evidencing relationships of the Company or any of its affiliates.	
D. Contingencies	
1. Copies of all correspondence with, and reports to, financial institutions during the past five years.	
23	

REQUESTED ITEM	STATUS / COMMENTS
III. FINANCIAL INFORMATION, ETC.	
E. Powers of Attorney and Letters of Authorization regarding the signing of contracts and other documents by or on behalf of the Company or any of its affiliates.	
F. Agreements relating to restrictions upon competition or restriction or preparation to restrict the ability of the Company or any of its affiliates to engage in any type of business or to operate in any geographic area.	
G. Any other significant contracts of the Company or any of its affiliates (including those that represent a commitment of the Company or any of its affiliates).	
III. FINANCIAL ACCOUNTING AND EXPENDITURES	
A. Financial statements for all of the period from years prior to the Company's inception, as well as the most recent twelve months.	
1. All financial statements for all of the period from years prior to the Company's inception, as well as the most recent twelve months.	
2. Current revenue, expense and capital expenditures budget of the Company and each of its affiliates.	
3. Cash flow projections for twelve years for the Company and each of its affiliates.	
4. Annual revenue aging analysis of the Company and each of its affiliates.	
5. If applicable, correspondence with accountants relating to audits, reviews or examinations of the Company and each of its affiliates since their respective inception, including accountancy letters or management and statutory letters furnished in connection with audits, reviews or examinations.	
6. Assets and liabilities of the Company or any of its affiliates not recorded in the most recent balance sheet.	
IV. REPORTS, PLANNING AND MATERIALS	
A. Management Reports	
1. The Company's current business or strategic plan and any long-range business plans.	
2. Copies of reports or studies (including any projections or forecasts) relating to any transaction of the type referred to in Sections A, F, G and H above.	
24	

Closing the Deal - “Due Diligence” – More \$, More Scrutiny

REQUESTED ITEM	STATUS/ COMMENTS
E. Bank Information	
1. Schedule of banking relationships of the Company or any of its affiliates.	
III. OTHER ASSURANCES	
To the extent not covered elsewhere in this list:	
A. Agreements relating to any significant acquisition or disposition of assets or business by the Company or any of its affiliates during the past five years.	
B. Letters of intent, memoranda of intent, offering materials and any other documentation for any contemplated financing or acquisition or disposition of equity, assets or business by the Company or any of its affiliates.	
C. All documents relating to any transactions or contracts between or among the Company and any of its affiliates and any of its or their direct, indirect, independent, subsidiaries or entities that are controlled by such parties.	
D. Present or pending joint venture or partnership agreements and other such arrangements in which the Company or any of its affiliates is a party or is otherwise involved.	
E. License agreements of the Company or any of its affiliates.	
F. Management or advisory contracts or arrangements for management, maintenance or servicing of the Company or any of its affiliates, or any of its facilities.	
G. Contracts and agreements for construction or restoration of facilities for the Company or any of its affiliates.	
H. Inventory and maintenance agreements with third parties relating to maintenance and other proprietary information of the Company or any of its affiliates.	
I. Consultation, brokerage, agency or similar contracts relating to the sale or procurement of goods or services by or on behalf of the Company or any of its affiliates.	
J. Engagement letters with financial advisors, investment bankers, auditors, business brokers or similar entities or other providers relating to any transaction of the type referred to in Sections A, B, F, G and I above.	
1101 - (NON-TRANSACTIONAL) - (PENDING)	23

REQUESTED ITEM	STATUS/ COMMENTS
K. Powers of Attorney and other instruments regarding the control of interests and other instruments by or on behalf of the Company or any of its affiliates.	
L. Agreements relating to restricting stock ownership or increasing or purporting to restrict the ability of the Company or any of its affiliates to engage in any type of business or to operate in any geographic area.	
M. Any other significant contracts of the Company or any of its affiliates (including those that represent a commitment of the Company or any of its affiliates).	
NH. FINANCIAL PERFORMANCE AND EXPENDITURES	
A. Financial statements for all completed fiscal years since the Company's inception, as well as the most recent interim periods, for the Company and any of its affiliates. Such statements should include changes in accounting methods from one period to another.	
B. Current revenue, expense and capital expenditures budget of the Company and each of its affiliates.	
C. Cash flow projections for future years for the Company and each of its affiliates.	
D. Accounts receivable aging analysis of the Company and each of its affiliates.	
E. If applicable, correspondence with accountants relating to audits, reviews or examinations of the Company and each of its affiliates since their respective inception, including accountants' letters to management and company officers delivered in connection with audits, reviews or examinations.	
F. Assets and liabilities of the Company or any of its affiliates not recorded on the its most recent balance sheet.	
XV. REPORTS, PLANNING AND MARKETING	
A. Management Reports	
1. The Company's current business or strategic plan and any long range business plans.	
2. Copies of reports or studies (including any projections or other forecasts) relating to the Company or any of its affiliates, financial condition, business operations.	
1101 - (NON-TRANSACTIONAL) - (PENDING)	24

REQUESTED ITEM	STATUS/ COMMENTS
including reports on:	
A. Provide and other reports or memoranda prepared by management or consultants for the Board of Directors or equivalent body of the Company or any of its affiliates or any committee thereof.	
B. Intellectual and Technical	
1. Schedule of top 20 customers and top 20 suppliers.	
To the extent not covered elsewhere in this list, copies of significant reports to or correspondence with the Board, major or senior government agency other than the Company's employees.	
B. Other Items	
B. Recent activities of the Company or any of its affiliates or its respective subsidiaries prepared by management, business, engineering, independent consultants, or other entities, including reports or studies, including marketing studies, industry trends, credit reports and other types of reports, forecasts or otherwise, relating to the Company or to its affiliates' technologies or products.	
E. Marketing	
1. Brand plans, launch plans, competitive product analyses, and marketing/distribution brochures prepared since the Company's inception relating to the Company or its affiliates' technologies or products.	
2. All sales or press releases issued by the Company or any of its affiliates, or any press releases received by third parties relating to the Company or its affiliates' technologies or products.	
XV. FINANCIAL	
A. Financial, state and local tax returns and IRS audit reports of the Company and each of its affiliates since its respective inception, and any agreements between the Company or any of its affiliates and the IRS regarding the manner of reporting for any years establishing authority in any state related to the above information.	
1101 - (NON-TRANSACTIONAL) - (PENDING)	25

Closing the Deal - “Due Diligence” – More \$, More Scrutiny

IP-Diligence-Requests¶

I. → Ownership-¶

- A. → Copies-of-all-invention-assignments¶
- B. → Copies-of-all-agreements-with-persons-or-entities-having-a-potential-to-make-inventive-contributions-¶
 - i. → Employment-agreements¶
 - ii. → Consultant-agreements¶
 - iii. → Scientific-advisory-board¶
 - iv. → Key-vendors¶
- C. → Identification-of-any-potential-ownership-leaks¶
 - i. → Prior-employment-or-assignment-obligations-of-inventors¶
 - ii. → Any-inventor-university-affiliations¶
 - iii. → Outgoing-obligations-in-NDA-/CDA-or-other-agreements¶
- D. → Licensing-Relationships¶
 - i. → A-listing-of-third-party-technology-in-the-device-and-any-remote-systems/software-as-well-as-corresponding-copies-of-all-in-license-agreements¶
 - ii. → Copies-of-all-out-license-agreements¶
 - iii. → For-Open-Source-Software-(OSS), a-listing-of-the-following-(sample-below):-¶
 - 1. → the-OSS-name-and-version¶
 - 2. → the-OSS-license,-version,-and-licensor¶
 - 3. → an-indication-of-whether-the-OSS-is-modified¶
 - 4. → an-indication-of-whether-the-OSS-is-distributed¶
 - 5. → an-indication-of-how-the-OSS-interacts-with-the-Target’s-code¶
- E. → Any-threatened-or-possible-challenges-to-inventorship¶
- F. → Any-pending-or-threatened-allegations-of-licensing-violations-or-breaches,-including-OSS-licenses¶

II. → Offensive-Portfolio-and-Technology- (“Patent-Scope”)¶

- A. → Copy-of-current-IP-status-report¶
- B. → Identification-of-which-independent-claims,-as-presently-written,-literally-cover-Target’s-device,-commercially-related-systems/software,-or-related-methods¶
- C. → Identification-of-specific-key-structural-or-performance-features-believed-to-drive-clinical-demand¶
- D. → Detailed-description-of-current-clinical-device-and-any-commercially-related-systems/software-(e.g.,-engineering-drawings,-assembly-drawings)¶
- E. → Description-of-revenue-model-(relative-gross-margins-and-dollar-volume-on-capital-equipment;-reusable;-one-time-use-disposables;-repair-or-replacement-components;-service-agreements)¶
- F. → Copy-of-any-description-of-the-device-or-its-use-in-any-S10(k)-or-other-FDA-submissions¶
- G. → Anticipated-US-regulatory-approval-date;-CE-Mark-and-launch-dates-in-US-and-OUS¶
- H. → Copies-of-all-patentability-opinions¶

III. → Commercial-Risk- (“Freedom-to-Operate”)¶

- A. → Identify-all-patent-searches-and-results¶
- B. → Copies-of-all-opinions-relating-to-patent-infringement-or-validity-of-third-party-patents¶
- C. → Identification-of-all-patents-or-applications-which-received-elevated-scrutiny¶
- D. → Identification-of-all-patent-monitoring-(e.g.,-patent,-application,-inventor,-company)-¶
- E. → Identification-of-all-known-competitors-or-potential-competitors¶
- F. → Identification-of-any-pending,-threatened,-possible-or-past-challenge-to-Target’s-ownership-of-or-right-to-use-intellectual-property¶
- G. → Identification-of-any-pending,-threatened,-possible-or-past-claim-of-infringement-of-any-intellectual-property-based-on-manufacture,-use-or-sale-of-any-product-or-service-of-Target.¶
- H. → Identification-of-any-letter-or-other-communication-from-any-third-party-notifying-the-Target-of-the-existence-of-a-patent-or-application-owned-or-licensed-by-the-third-party.¶

Sample-Open-Source-Software-Table¶


¶	NAME¶	LICENSE¶	DISTRIBUTION¶	MODIFICATION¶	INTEGRATION¶
¶	OSS name and version number¶	OSS license, version number, and licensor¶	Is the OSS distributed (e.g., included in a product that is delivered to clients, a software-executable or API that is downloaded by clients to be used at the clients’ sites)¶	Was the OSS modified in any way? if yes, please explain¶	Is the OSS used with proprietary code? if so, how is it integrated (e.g., dynamically linked, statically linked, compiled with the product code, etc.)¶
1. →	MyLib.OSS, v. 2.1a	BSD 1.0¶ Kia Smitha	Yes, it is included in the clinical device	No modifications—used as downloaded a	Yes, stand-alone library that is dynamically linked to the company’s codes
2. →	¶	¶	¶	¶	¶

The Opportunity


- Assisting with your FIRST PATENT APPLICATION
 - Add value to the most vulnerable part of the portfolio
 - ANY Engineer (UCI Engineering Student) can write more than HALF of a patent application

Parts of a Patent

Description





(Hardware)




(Software)

Claims



Extreme Value Portfolio – 31 “Continuations”





One of Masimo's Patent families, 31 "Continuations" of one patent application. Value = \$1B jury verdicts.

Recommendations to Universities

- **Add Invention Disclosures/Patent Application Drafting to Writing Curriculum**
 - **ENGR 190W. Communications in the Professional World. 4 Units.** Upper-division technical writing course including the development of presentation skills. Effective communication with a range of audiences, including invention disclosures and patent applications. Recognition of ethical and professional responsibilities for engineers.
 - *(Note – “Invention” does not appear in the UCI engineering course catalogs)*
 - Ask Local Patent Attorneys for Free Lectures/Lesson Plan

Recommendations to Student Entrepreneurs

- Read Sample Patents!
- Ask Attorney for (free) Lunch and Lesson
- Help Draft First Patent Application as Much as Possible



Result: Excellent Patent Application on Budget!

Michael Guiliana Michael.Guiliana@knobbe.com
(949) 721-6384



Orange County



Los Angeles



New York



San Diego




San Francisco



Seattle



Silicon Valley



Washington DC